International Psoriasis Council

Advancing Knowledge. Enhancing Care.

Advancing Knowledge. Enhancing Care.

Commentary: Psoriasis comprehensive review

Professor Iversen, an IPC councilor since 2009, and since 2017 board member of the IPC.

Lars Iversen, MD, DMSc
Aarhus University Hospital
Aarhus, Denmark
IPC Board Member

PUBLICATION

Psoriasis. Griffiths C, Armstrong A, Gudjonsson J, Barker J. Lancet. vol. 397. no. 10281. 2021 Apr; 397: 1301–15. doi: 10.1016/s0140-6736(20)32549-6.

COMMENTARY

In the April 2021 issue of the Lancet, four of our esteemed colleagues in the IPC published an updated and comprehensive review of the current pieces of knowledge on psoriasis.

It is a very well-written review covering all aspects of psoriasis spanning from epidemiology and pathophysiology to clinical presentation, associated diseases, and the management of psoriasis.  Alongside an update of the most recently published literature in the field of psoriasis, the manuscript is also accompanied by clear clinical pictures, figures that elegantly explain the pathogenesis of psoriasis, and tables that provide a good overview of the different treatment options.

The review is up-to-date and discusses the current knowledge and challenges in managing psoriasis during the SARS-CoV-2 pandemic and nicely points out future directions of psoriasis research by highlighting unresolved questions, new developments, and unmet medical needs. Because of the comprehensive nature of this manuscript, it appeals to those who want to gain an overview of the various aspects of psoriasis and those who are searching for an in-depth understanding of specific aspects of psoriasis and its subtypes such as their different pathophysiologies.

This manuscript will undoubtedly serve as a critical reference paper in the field of psoriasis in the coming years.

Categories

Recent Posts

Shining a Spotlight on our 2022 Fellows: Get to Know the Future Leaders in Psoriasis – Mona El-Kalioby, MBBCh, MSc, MD

Psoriasis and the Pandemic: Lessons Learned from PsoProtect

Boehringer Ingelheim’s SPEVIGO® Receives Breakthrough Therapy Designation (BTD) from the United States Food and Drug Administration (FDA)

Also Read

Apremilast

Commentary: Preclinical and Clinical Evidence for Suppression of Alcohol Intake by Apremilast

A host of factors is important to consider in the personalized treatment of psoriasis. It is advantageous if a treatment is effective in psoriasis and has beneficial effects on associated conditions. This recent literature publication has highlighted that apremilast, beyond its anti-psoriatic properties, positively impacts excessive alcohol consumption. Read the expert opinion of IPC Board Member Johann Gudjonsson, MD, PhD.

Read More

Subscribe to the IPC Newsletter

Stay up-to-date on the latest research, news, and upcoming events right in your inbox.